Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nimrat Bains

Physician Assistant Belpre, OH Physician Assistant

NPI 1093285629 CMS profile 10676869

803 Farson St Ste 100, Belpre, OH 45714

Open in the dashboard

General payments

$2,498

72 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nimrat Bains of Belpre, OH is reported in the CMS Open Payments database as having received $2,498 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,641 37
2024 General $116 5
2022 General $144 3
2021 General $597 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nimrat Bains
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nimrat Bains were reported at $1,641. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nimrat Bains Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $597 $132 $37–$438 $132
2022 $144 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $116 $178 $55–$600 $164
2025 $1,641 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,027 10 payments
  2. Novo Nordisk Inc $431 16 payments
  3. Insulet Corporation $323 10 payments
  4. Sanofi-Aventis U.S. LLC $139 3 payments
  5. Lilly USA, LLC $82 5 payments
  6. Dexcom, Inc. $55 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $43 3 payments
  8. Corcept Therapeutics $41 2 payments
  9. AstraZeneca Pharmaceuticals LP $41 3 payments
  10. Amgen Inc. $36 2 payments
  11. Other $279 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,906 71 payments
  2. Travel and Lodging $592 1 payment
Products named General payments · program years 2021–2025
  1. MINIMED 780G $992 8 payments
  2. Omnipod $323 10 payments
  3. RYBELSUS $257 11 payments
  4. Ozempic $178 11 payments
  5. Wegovy $115 1 payment
  6. Dexcom G6 Transmitter $55 2 payments
  7. Saxenda $44 3 payments
  8. Korlym $41 2 payments
  9. FARXIGA $41 3 payments
  10. TRULICITY $36 2 payments
  11. Other $537 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

5,747

Median for Physician Assistant: 241

Drug cost

$3,153,096

Median for Physician Assistant: $4,110

Branded share of claims

78.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 527 $590,684
Ozempic Semaglutide Brand 506 $541,884
Trulicity Dulaglutide Brand 396 $409,548
Jardiance Empagliflozin Brand 402 $349,438
Farxiga Dapagliflozin Propanediol Brand 178 $152,072
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 77 $142,165
Tresiba Flextouch U-200 Insulin Degludec Brand 166 $137,450
Tresiba Flextouch U-100 Insulin Degludec Brand 101 $68,331
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 84 $67,971
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 134 $66,517

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$41,259

Medicare's payments for the services billed

Medicare patients

335

Average age 69

Services billed

1,098

203 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 47%
Chronic kidney disease 44%
Depression 35%
Heart failure 26%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record